Opdivo receives two new Health Canada approvals

2 November 2021 -  Today Bristol Myers Squibb Canada announces two recent Health Canada approvals for Opdivo (nivolumab).  ...

Read more →

Kite's Tecartus (brexucabtagene autoleucel) authorised by Health Canada for the treatment of relapsed or refractory mantle cell lymphoma

28 October 2021 - Tecartus is first CAR T therapy in mantle cell lymphoma and Kite becomes the first company ...

Read more →

New Sarclisa (isatuximab) combination now approved by Health Canada for adults with relapsed and/or refractory multiple myeloma

13 October 2021 - The approval is based on data from the Phase 3 IKEMA trial. ...

Read more →

PharmaMar announces the approval of Zepzelca (lurbinectedin) for the treatment of relapsed stage III or metastatic small cell lung cancer in Canada

30 September 2021 - Lurbinectedin to become commercially available in Canada in the coming months. ...

Read more →

Helsinn Group and BridgeBio Pharma’s affiliate QED Therapeutics announce Health Canada conditional approval of Truseltiq (infigratinib) for patients with cholangiocarcinoma

29 September 2021 - Health Canada issues conditional approval of Truseltiq under Project Orbis (27 September 2021). ...

Read more →

Gilead marks fifth approval for Trodelvy in metastatic triple negative breast cancer under Project Orbis initiative with Health Canada authorisation

27 September 2021 - Antibody-drug conjugate Trodelvy is first treatment to show survival benefit versus standard of care in metastatic triple ...

Read more →

Canadian cancer patients have new affordable treatment option

27 September 2021 - Apobiologix expanded its leadership in Canada's biosimilar market with the approval of its first therapeutic treatment, Bambevi.  ...

Read more →

Incyte announces Health Canada conditional approval of Pemazyre (pemigatinib) as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma

17 September 2021 - Incyte today announced that Health Canada has granted a Notice of Compliance with conditions for Pemazyre (pemigatinib), ...

Read more →

Health Canada approves Lumakras (sotorasib), the first and only targeted treatment for patients with KRAS G12C mutated locally advanced or metastatic non--small cell lung cancer

14 September 2021 - Once daily dosing option now available to address KRAS G12C, a driver of tumour growth found ...

Read more →

Natco Pharma (Canada) announces the launch of Nat-Lenalidomide capsules, the first generic alternative to Revlimid

1 September 2021 - Nat-Lenalidomide expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to ...

Read more →

Health Canada grants marketing authorisation for Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

24 August 2021 - Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an ...

Read more →

BeiGene announces approval in Canada of Brukinsa (zanubrutinib) for the treatment of patients with mantle cell lymphoma

26 July 2021 - Second approval for BTK inhibitor Brukinsa in Canada. ...

Read more →

New treatment authorised and available for Canadians with HER2 positive breast cancer

20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...

Read more →

Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia

7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...

Read more →

Knight Therapeutics announces Health Canada approval for Nerlynx (neratinib) to treat HER2 positive metastatic breast cancer

6 July 2021 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the ...

Read more →